BioCentury | Feb 21, 2011
Financial News

Biotec Pharmacon completes private placement

Biotec Pharmacon ASA (OSE:BIOTEC), Tromso, Norway Business: Dermatology, Cancer, Other Date completed: 2/11/11 Type: Private placement Raised: NOK7.6 million ($1.3 million) Shares: 1.2 million Price: NOK6.30 Shares after offering: 28.3 million Placement agent: SEB Enskilda...
BioCentury | Jan 31, 2011
Company News

Biotec Pharmacon dermatology news

...it plans to partner the product and expects to launch it in 1H12. In 2009, Biotec Pharmacon...
...SBG inactive in Phase III trials (see BioCentury, Dec. 7, 2009 & Oct. 4, 2010). Biotec Pharmacon ASA...
BioCentury | Jan 3, 2011
Financial News

Biotec Pharmacon proposes private placement

Biotec Pharmacon ASA (OSE: BIOTEC), Tromso, Norway Business: Dermatology, Cancer, Other Date announced: 12/23/10 Type: Private placement To be raised: Up to NOK7.6 million ($1.3 million) Shares: 1.2 million Price: NOK6.30 Shares outstanding prior: 27.1...
BioCentury | Jan 3, 2011
Financial News

Biotec Pharmacon completes private placement

Biotec Pharmacon ASA (OSE: BIOTEC), Tromso, Norway Business: Dermatology, Cancer, Other Date completed: 12/23/10 Type: Private placement Raised: NOK22.1 million ($3.7 million) Shares: 3.5 million Price: NOK6.30 Shares after offering: 27.1 million WIR Staff cancer...
BioCentury | Oct 4, 2010
Clinical News

Biotec Pharmacon preclinical data

...were used in Phase III testing non-significantly improved wound healing vs. vehicle controls. In February, Biotec Pharmacon...
...target ulcers healed at week 8 vs. SOC plus placebo (see BioCentury, Dec. 7, 2009). Biotec Pharmacon ASA...
BioCentury | Mar 15, 2010
Company News

Biotec Pharmacon management update

Biotec Pharmacon ASA (OSE:BIOTEC), Tromso, Norway Business: Dermatology, Cancer, Other Hired: Svein Lien as CEO, formerly CEO of Axis-Shield plc ; he replaces Lars Viksmoen, who resigned WIR Staff cancer Dermatology...
BioCentury | Mar 8, 2010
Clinical News

SBG: Additional Phase III data

...studies with SBG in a number of product containers to confirm the hypothesis. In November, Biotec Pharmacon...
...BioCentury, Dec. 7, 2009). SBG is also in Phase III testing for oral mucositis (OM). Biotec Pharmacon ASA...
BioCentury | Jan 11, 2010
Company News

Biotec Pharmacon, Sana Pharma A/S deal

...$3.8 million) for the nine months ended Sept. 30, 2009. Creo Advisors A/S advised Biotec Pharmacon. Biotec Pharmacon...
...said the move allows it to focus on its core pharmaceuticals and marine chemicals businesses. Biotec Pharmacon...
...soluble beta-1,3/1,6-glucan is also in Phase III testing for oral mucositis. At Sept. 30, 2009, Biotec Pharmacon...
BioCentury | Jan 4, 2010
Finance

Restructuring watch

...benign and malignant pelvic masses; cash includes $43.1M raised in a December private placement 12/11/09 Biotec Pharmacon ASA...
BioCentury | Jan 4, 2010
Finance

4Q setbacks

...patients who no longer respond to a DMARD, citing risk of progressive multifocal leukoencephalopathy (PML) Biotec Pharmacon ASA...
Items per page:
1 - 10 of 35
BioCentury | Feb 21, 2011
Financial News

Biotec Pharmacon completes private placement

Biotec Pharmacon ASA (OSE:BIOTEC), Tromso, Norway Business: Dermatology, Cancer, Other Date completed: 2/11/11 Type: Private placement Raised: NOK7.6 million ($1.3 million) Shares: 1.2 million Price: NOK6.30 Shares after offering: 28.3 million Placement agent: SEB Enskilda...
BioCentury | Jan 31, 2011
Company News

Biotec Pharmacon dermatology news

...it plans to partner the product and expects to launch it in 1H12. In 2009, Biotec Pharmacon...
...SBG inactive in Phase III trials (see BioCentury, Dec. 7, 2009 & Oct. 4, 2010). Biotec Pharmacon ASA...
BioCentury | Jan 3, 2011
Financial News

Biotec Pharmacon proposes private placement

Biotec Pharmacon ASA (OSE: BIOTEC), Tromso, Norway Business: Dermatology, Cancer, Other Date announced: 12/23/10 Type: Private placement To be raised: Up to NOK7.6 million ($1.3 million) Shares: 1.2 million Price: NOK6.30 Shares outstanding prior: 27.1...
BioCentury | Jan 3, 2011
Financial News

Biotec Pharmacon completes private placement

Biotec Pharmacon ASA (OSE: BIOTEC), Tromso, Norway Business: Dermatology, Cancer, Other Date completed: 12/23/10 Type: Private placement Raised: NOK22.1 million ($3.7 million) Shares: 3.5 million Price: NOK6.30 Shares after offering: 27.1 million WIR Staff cancer...
BioCentury | Oct 4, 2010
Clinical News

Biotec Pharmacon preclinical data

...were used in Phase III testing non-significantly improved wound healing vs. vehicle controls. In February, Biotec Pharmacon...
...target ulcers healed at week 8 vs. SOC plus placebo (see BioCentury, Dec. 7, 2009). Biotec Pharmacon ASA...
BioCentury | Mar 15, 2010
Company News

Biotec Pharmacon management update

Biotec Pharmacon ASA (OSE:BIOTEC), Tromso, Norway Business: Dermatology, Cancer, Other Hired: Svein Lien as CEO, formerly CEO of Axis-Shield plc ; he replaces Lars Viksmoen, who resigned WIR Staff cancer Dermatology...
BioCentury | Mar 8, 2010
Clinical News

SBG: Additional Phase III data

...studies with SBG in a number of product containers to confirm the hypothesis. In November, Biotec Pharmacon...
...BioCentury, Dec. 7, 2009). SBG is also in Phase III testing for oral mucositis (OM). Biotec Pharmacon ASA...
BioCentury | Jan 11, 2010
Company News

Biotec Pharmacon, Sana Pharma A/S deal

...$3.8 million) for the nine months ended Sept. 30, 2009. Creo Advisors A/S advised Biotec Pharmacon. Biotec Pharmacon...
...said the move allows it to focus on its core pharmaceuticals and marine chemicals businesses. Biotec Pharmacon...
...soluble beta-1,3/1,6-glucan is also in Phase III testing for oral mucositis. At Sept. 30, 2009, Biotec Pharmacon...
BioCentury | Jan 4, 2010
Finance

Restructuring watch

...benign and malignant pelvic masses; cash includes $43.1M raised in a December private placement 12/11/09 Biotec Pharmacon ASA...
BioCentury | Jan 4, 2010
Finance

4Q setbacks

...patients who no longer respond to a DMARD, citing risk of progressive multifocal leukoencephalopathy (PML) Biotec Pharmacon ASA...
Items per page:
1 - 10 of 35